Wordt geladen...
Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: a Randomized Phase II Study
PURPOSE: Increased growth factor signaling may contribute to tamoxifen resistance. This randomized Phase II trial assessed tamoxifen plus placebo or the EGFR inhibitor gefitinib in ER-positive metastatic breast cancer. EXPERIMENTAL DESIGN: Patients with newly metastatic disease or recurring after ad...
Bewaard in:
| Hoofdauteurs: | , , , , , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2011
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3074404/ https://ncbi.nlm.nih.gov/pubmed/21220480 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-1869 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|